not tagged
northwest biotherapeutics
['nwbo']
 pfs is one of the five measures fda accepts. if you read the asco trial data releases a large percent use pfs as the endpoint. $nwbo tossed it because they failed to meet it. their "new" endpoints rely on confounded os data, biased comparator and dosing issues with recurrent os.